JAMA+ AI Conversations

Derek Angus, MD, MPH, a Senior Editor at JAMA and a leading expert on AI in healthcare, joins Roy Perlis to explore AI's transformative potential in medical settings. They discuss the delicate balance between the excitement for AI advancements and necessary caution regarding regulation and evaluation. Angus highlights the need for innovative methods to assess AI tools, the pitfalls of rapid adoption of inadequately tested technologies, and the importance of operational AI in improving patient outcomes. The conversation provides crucial insights into the future of AI in health.

Explore how AI is transforming health care by 2026, from detecting hidden brain lesions to enhancing medical imaging. Discover the debate on AI's role in radiology and its potential to reduce clinician burnout. Dive into innovative studies showcasing AI translation capabilities and confronting public perceptions of AI in medicine. Learn about the push for rigorous trials to validate AI health tools and the rise of direct-to-consumer AI products, highlighting both opportunities and risks for the future.

Dr. Michael Howell, Chief Clinical Officer at Google, dives into the intersection of AI and healthcare. He discusses the rapid advancements in AI, tackling the challenge of addressing 15% of novel search queries. Howell emphasizes the importance of balancing innovation with safety and outlines Google's commitment to rigorous testing and peer-reviewed guidelines. He also shares insights for early-career professionals in healthcare technology, advocating for a future where AI enhances patient empowerment and clinician support.

Linda Moy, inaugural vice chair of AI for NYU's Department of Radiology, dives into the transformative role of AI in women's health. She discusses the promise of AI in enhancing diagnostic accuracy in radiology and improving early cancer detection, particularly in mammography. Moy emphasizes the importance of transparency with patients about AI's role in diagnostics and highlights the need for rigorous testing to ensure equitable healthcare. Additionally, she talks about innovative concepts like 'digital twins' to enhance treatment predictions.

Michelle Mello, JD, PhD, MPhil, is a professor at Stanford University specializing in law and health policy. She discusses the ethical duty of healthcare organizations to disclose AI usage to patients. Mello emphasizes the current mistrust patients have regarding AI's role in their care. The conversation explores the complexities of consent and the necessity for transparent communication to enhance patient trust. Additionally, she advocates for involving patients in AI governance to create a more informed and engaged healthcare community.

David Rhew, Global Chief Medical Officer at Microsoft and Stanford adjunct professor, shares his fascinating journey from clinical practice to tech leadership. He discusses the rapid evolution of AI in healthcare, emphasizing the need for AI training in medical education. Rhew humorously illustrates the risks of over-relying on AI, likening it to becoming too dependent on GPS. He also highlights how AI can revolutionize care for underserved populations and improve drug discovery, advocating for effective adoption strategies.

Maja Matarić, a pioneering computer scientist and professor at USC, shares her expertise in socially assistive robotics. She highlights how AI is transforming therapy for autism, depression, and more. The importance of robots like Blossom is discussed, emphasizing their ability to facilitate dynamic human-robot interactions. Maja also touches on the impact of physical presence against isolation, especially during the pandemic, and envisions a future where affordable robots combat loneliness at home, enhancing well-being for all.

Daniel Lindsay, an economist from QIMR in Queensland, dives into the innovative world of 3D total-body photography for melanoma detection. He discusses the recent study on the cost-effectiveness of this technology compared to traditional methods. The conversation touches on the role of AI in enhancing lesion detection while navigating the challenges of its economic evaluation. Lindsay also highlights unexpected findings related to excisions and the implications for clinical practice, emphasizing the need for reevaluating healthcare strategies.

Robert S. Rudin, a Senior Information Scientist at RAND and a Professor of Policy Analysis, discusses a revolutionary AI app for asthma symptom tracking. He highlights how the app aims to enhance patient adherence and streamline communication with healthcare providers. The conversation dives into the collaborative design process behind the app and its user-centered focus. Rudin also addresses accessibility challenges and envisions how this technology could evolve to monitor other chronic conditions, transforming digital health management.

The Dana-Farber Cancer Institute (DFCI)’s MatchMiner tool was developed to increase historically low clinical trial enrollment rates in adults with cancer. Roy Perlis, MD, MSc, Editor in Chief of JAMA+ AI, spoke with Kenneth Kehl, MD, MPH, about his recent study published in JAMA Network Open evaluating the AI tool’s ability to fulfill its purpose through genome sequencing. Related Content: Clinical Trial Notifications Triggered by Artificial Intelligence–Detected Cancer Progression Considerations in Translating AI to Improve Care How AI Could Increase Clinical Trial Enrollment in Adults With Cancer